Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LIPA | P38571 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223501 | 0.87 | KDM4E (0.39) | — | |
| SCHEMBL19652110 | 0.85 | NCF1 (0.38) | RIPK1CYP2D6DPP4DPP8DPP9 | |
| SCHEMBL19652132 | 0.84 | BCHE (0.36) | CYP2D6DPP4DPP8DPP9DPP7 | |
| SCHEMBL23560054 | 0.82 | SMN1; SMN2 (0.42) | CYP2D6DPP4DPP8DPP9DPP7 | |
| SCHEMBL19652117 | 0.81 | HRH3 (0.39) | CYP2D6DPP4DPP8DPP9DPP7 | |
| SCHEMBL19652102 | 0.81 | SIGMAR1 (0.36) | ALOX5CYP2D6DPP4DPP8DPP9 | |
| SCHEMBL26424530 | 0.80 | ADORA2A (0.33) | RIPK1CYP2D6DPP4DPP8DPP9 | |
| SCHEMBL19652167 | 0.79 | ACHE (0.44) | — | |
| SCHEMBL9954309 | 0.77 | — | — | |
| SCHEMBL23872422 | 0.77 | ALOX5 (0.38) | ALOX5THRATHRBLIPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4177249-A1 | IMMUNOMODULATOR | Hitgen Inc. (CN) | 2023-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | ALOX5 340/4885RIPK1 2674/4885PTGIR 448/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | ALOX5 237/4885RIPK1 2561/4885PTGIR 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.